Literature DB >> 9881891

Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy.

K Sato1, M Shiraki.   

Abstract

Saccharaed ferric oxide (SFO)-induced osteomalacia develops when excessive SFO infusions are administrated to patients with anemia for prolonged periods for a few years. The small particles and almost neutral saccharide of SFO filter through the glomerular tufts into the renal tubules, resulting in impairment of proximal renal tubular function, particularly renal reabsorption of phosphate and 1alpha-hydroxylase activity, resulting in decreased serum levels of phosphorus and active vitamin D, both of which lead to development of hypophosphatemic osteomalacia. Furthermore, SFO, at concentrations attainable in serum, exacerbates the osteomalacia by inhibiting bone formation directly. In contrast to itai-itai disease, another iatrogenic osteomalacia due to cadmium nephropathy [44], the proximal renal tubular function impairment induced by SFO is reversible simply by discontinuing the nephrotoxin, which is followed by improvement of all the clinical manifestations, except bone deformities. So far, SFO-induced osteomalacia, that is, SFO-induced osteopathy due to nephropathy, has been reported only in Japan, probably due to the lax surveillance system of the health insurance scheme. All physicians who prescribe SFO should be aware of its severe adverse effects. We hope that such iatrogenic osteomalacia caused by abusive infusion of SFO will never again be reported in our country.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881891     DOI: 10.1507/endocrj.45.431

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  16 in total

Review 1.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

2.  Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

Authors:  Emily G Farrow; Xijie Yu; Lelia J Summers; Siobhan I Davis; James C Fleet; Matthew R Allen; Alexander G Robling; Keith R Stayrook; Victoria Jideonwo; Martin J Magers; Holly J Garringer; Ruben Vidal; Rebecca J Chan; Charles B Goodwin; Siu L Hui; Munro Peacock; Kenneth E White
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

3.  Iron, oxidative stress, and clinical outcomes.

Authors:  Rajiv Agarwal
Journal:  Pediatr Nephrol       Date:  2007-11-21       Impact factor: 3.714

4.  The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients.

Authors:  Serpil Muge Deger; Yasemin Erten; Ozge Tugce Pasaoglu; Ulver Boztepe Derici; Kadriye Altok Reis; Kursad Onec; Hatice Pasaoglu
Journal:  Clin Exp Nephrol       Date:  2012-11-20       Impact factor: 2.801

Review 5.  New Therapies for Hypophosphatemia-Related to FGF23 Excess.

Authors:  Diana Athonvarangkul; Karl L Insogna
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

Review 6.  Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.

Authors:  John A Glaspy; Myles Wolf; William E Strauss
Journal:  Adv Ther       Date:  2021-05-30       Impact factor: 3.845

Review 7.  Intravenous iron administration and hypophosphatemia in clinical practice.

Authors:  S Hardy; X Vandemergel
Journal:  Int J Rheumatol       Date:  2015-04-27

8.  Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.

Authors:  Merche Prats; Ramon Font; Carmen García; Carmen Cabré; Manel Jariod; Alberto Martinez Vea
Journal:  BMC Nephrol       Date:  2013-07-31       Impact factor: 2.388

9.  A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).

Authors:  Walter Reinisch; Michael Staun; Rakesh K Tandon; Istvan Altorjay; Andrew V Thillainayagam; Cornelia Gratzer; Sandeep Nijhawan; Lars L Thomsen
Journal:  Am J Gastroenterol       Date:  2013-10-22       Impact factor: 10.864

Review 10.  Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.

Authors:  Philip A Kalra; Sunil Bhandari
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.